Ziogas et al., 2023 - Google Patents
Comparison of invasive pancreatic ductal adenocarcinoma versus intraductal papillary mucinous neoplasm: a national cancer database analysisZiogas et al., 2023
View HTML- Document ID
- 2020376265827024689
- Author
- Ziogas I
- Rodriguez Franco S
- Schmoke N
- Meguid C
- Murphy C
- Al-Musawi M
- Alexopoulos S
- Schulick R
- Del Chiaro M
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary This study aimed to compare the characteristics, management, and overall survival of pancreatic ductal adenocarcinoma (PDAC) vs. invasive intraductal papillary mucinous neoplasm (IPMN) using the National Cancer Database in the US. This study …
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/20—Education
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
- G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/20—Handling natural language data
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/10—Office automation, e.g. computer aided management of electronic mail or groupware; Time management, e.g. calendars, reminders, meetings or time accounting
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kasymjanova et al. | The impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian academic center: a retrospective chart review | |
Ziogas et al. | Comparison of invasive pancreatic ductal adenocarcinoma versus intraductal papillary mucinous neoplasm: a national cancer database analysis | |
Singh et al. | NCDB Analysis of Melanoma 2004–2015: epidemiology and outcomes by subtype, sociodemographic factors impacting clinical presentation, and Real-World Survival Benefit of Immunotherapy approval | |
Borkowska et al. | Clinicopathological features and prognostic factors of primary acral melanomas in Caucasians | |
Liu et al. | Real-world implications of nonbiological factors with staging, prognosis and clinical management in colon cancer | |
McGinnis et al. | Survival outcomes of pancreatic intraepithelial neoplasm (PanIN) versus intraductal papillary mucinous neoplasm (IPMN) associated pancreatic adenocarcinoma | |
Kim et al. | Primary angiosarcoma of the breast: a single-center retrospective study in Korea | |
Mataki et al. | Clinical benefits of conversion surgery for unresectable pancreatic ductal adenocarcinoma: A single-institution, retrospective analysis | |
Nizam et al. | Overall survival and adjuvant therapy in women with ovarian carcinosarcoma: a single-institution experience | |
Graham et al. | Chemotherapy and survival in patients with primary high-grade extremity and trunk soft tissue sarcoma | |
Blaj et al. | Prognostic Factors in Pseudomyxoma Peritonei with Emphasis on the Predictive Role of Peritoneal Cancer Index and Tumor Markers | |
Shinohara et al. | Clinicopathological characteristics and survival outcomes of patients with buccal squamous cell carcinoma: Results of a multi-institutional study | |
Kim et al. | Predictors of recurrence in patients with papillary thyroid carcinoma: does male sex matter? | |
Choi et al. | Repeated Pancreatectomy for isolated local recurrence in the remnant pancreas following radical pancreatectomy for pancreatic ductal adenocarcinoma: A pooled analysis | |
Ito et al. | Narrow-margin excision for invasive acral melanoma: is it acceptable? | |
Tilki et al. | Salvage radiotherapy versus observation for biochemical recurrence following radical prostatectomy for prostate cancer: a matched pair analysis | |
Shih et al. | Prognostic significance of the extranodal extension of regional lymph nodes in stage III-N2 non-small-cell lung cancer after curative resection | |
Kim et al. | Bilaterality as a Risk Factor for Recurrence in Papillary Thyroid Carcinoma | |
Jooste et al. | Management and outcomes of pancreatic cancer in french real-world clinical practice | |
Sakamoto et al. | Treatment and Prognosis of Oral Cancer Patients with Confirmed Contralateral Neck Metastasis: A Multicenter Retrospective Analysis | |
Kwon et al. | Number of tumor foci as a risk factor for recurrence in papillary thyroid carcinoma: does it improve predictability? | |
Franchi et al. | Treatment patterns, clinical outcomes and healthcare costs of advanced non-small cell lung cancer: a real-world evaluation in Italy | |
Underwood et al. | Changing practice patterns and improving survival for patients with pancreatic ductal adenocarcinoma | |
Goksu et al. | Racial/ethnic disparities and survival characteristics in non-pancreatic gastrointestinal tract neuroendocrine tumors | |
Yang et al. | Treatment sequences in patients with recurrent or metastatic head and neck squamous cell carcinoma: cetuximab followed by immunotherapy or vice versa |